Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chinese State Officials Say New Formulary Will See Some 500 Entries

This article was originally published in PharmAsia News

Executive Summary

Chinese government sources revealed that the new national Essential Drug List will include some 500 medicines, 100 short of market estimates.

Chinese government sources revealed that the new national Essential Drug List will include some 500 medicines, 100 short of market estimates. Additionally, officials noted that government procurements will focus more on drug quality due to concerns that the existing price-favoring practice has led to losses for pharmaceutical companies, supply shortages, and substandard drug quality. Furthermore, they stressed that grassroots health institutes can prescribe non-EDL treatments. These new developments are expected to benefit quality drug producers, as well as non-grassroots medical institutions. One industry expert indicated that currently, EDL medicines account for 10% of China’s overall drug sales. (Click Here For More - Chinese Language)

"New EDL To Expand To 500 Entries" - menet.com.cn (4/11/2012)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC080795

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel